Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-deamino-8-d-arginine Vasopressin
2. 1-desamino-8-arginine Vasopressin
3. Acetate, Desmopressin
4. Adiuretin
5. Adiuretin Sd
6. Apo-desmopressin
7. Arginine Vasopressin, Deamino
8. Ddavp
9. Deamino Arginine Vasopressin
10. Desmogalen
11. Desmopressin
12. Desmopressin Monoacetate
13. Desmopressin Monoacetate, Trihydrate
14. Desmopressine Ferring
15. Desmospray
16. Desmotabs
17. Ferring, Desmopressine
18. Minirin
19. Minurin
20. Monoacetate, Desmopressin
21. Monoacetate, Trihydrate Desmopressin
22. Nocutil
23. Octim
24. Octostim
25. Trihydrate Desmopressin Monoacetate
26. Vasopressin, 1-deamino-8-d-arginine
27. Vasopressin, 1-desamino-8-arginine
28. Vasopressin, Deamino Arginine
1. Octostim
2. Minirin
3. Ddavp
4. Stimate
5. Concentraid
6. Desmopressin Acetate Anhydrous
7. Noctiva
8. 62288-83-9
9. Ddavp (needs No Refrigeration)
10. Desmospray
11. Anhydrous Desmopressin Acetate
12. Desmopressin Acetate Preservative Free
13. Desmopressin Acetate (needs No Refrigeration)
14. 1k12647sfc
15. Desmopressin Acetate Hydrate
16. Desmotabs
17. Minirine
18. Nocutil
19. Octim
20. Desmopressin Acetate Trihydrate
21. Demopressin Acetate
22. Ddavp Nasal Spray
23. Ddavp Rhinal Tube
24. Stimate Nasal Spray
25. Noqdirna
26. Presinex
27. Desmomelt
28. Unii-1k12647sfc
29. Desmopressin Acetate [usan:jan]
30. Chembl1200556
31. Dtxsid4046864
32. 16679-58-6(free Base)
33. Desmopressin Acetate [mi]
34. Stimate (needs No Refrigeration)
35. Ex-a4285
36. 1-(3-mercaptopropionic Acid)-8-d-arginine Vasopression Monoacetate
37. Bdbm50247923
38. Mfcd00133962
39. Akos025311518
40. Ccg-270644
41. Desmopressin Monoacetate Anhydrous
42. Anhydrous Desmopressin Acetate [mart.]
43. (deamino-cys1,d-arg8)-vasopressin Acetate
44. 789d983
45. Q27252517
46. 1-(3-mercaptopropionic Acid)-8-d-arginine-vasopressin Monoacetate (salt)
47. Vasopressin, 1-(3-mercaptopropanoic Acid)-8-d-arginine-, Monoacetate (salt)
48. Vasopressin,1-(3-mercaptopropanoic Acid)-8-d-arginine-,monoacetate(salt)(9ci)
| Molecular Weight | 1129.3 g/mol |
|---|---|
| Molecular Formula | C48H68N14O14S2 |
| Hydrogen Bond Donor Count | 14 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 19 |
| Exact Mass | 1128.44808525 g/mol |
| Monoisotopic Mass | 1128.44808525 g/mol |
| Topological Polar Surface Area | 526 Ų |
| Heavy Atom Count | 78 |
| Formal Charge | 0 |
| Complexity | 2070 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Desmopressin acetate |
| Drug Label | Desmopressin Nasal Spray Solution USP, 0.01% is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. The structural formula for the active ingredient is:Mol. w... |
| Active Ingredient | Desmopressin acetate |
| Dosage Form | Injectable; Spray, metered; Tablet; Solution |
| Route | Nasal; oral; Injection; Oral |
| Strength | 0.01mg/spray; 0.004mg/ml; 0.2mg; 0.01%; 0.1mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Glenmark Generics; Teva Pharms; Hospira; Actavis Labs Fl; Apotex; Bausch And Lomb; Sun Pharm Inds; Teva Pharms Usa; Ferring |
| 2 of 2 | |
|---|---|
| Drug Name | Desmopressin acetate |
| Drug Label | Desmopressin Nasal Spray Solution USP, 0.01% is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. The structural formula for the active ingredient is:Mol. w... |
| Active Ingredient | Desmopressin acetate |
| Dosage Form | Injectable; Spray, metered; Tablet; Solution |
| Route | Nasal; oral; Injection; Oral |
| Strength | 0.01mg/spray; 0.004mg/ml; 0.2mg; 0.01%; 0.1mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Glenmark Generics; Teva Pharms; Hospira; Actavis Labs Fl; Apotex; Bausch And Lomb; Sun Pharm Inds; Teva Pharms Usa; Ferring |
Antidiuretic Agents
Agents that reduce the excretion of URINE, most notably the octapeptide VASOPRESSINS. (See all compounds classified as Antidiuretic Agents.)
Hemostatics
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-06
Pay. Date : 2012-12-03
DMF Number : 16947
Submission : 2003-11-07
Status : Active
Type : II
Certificate Number : CEP 2006-113 - Rev 04
Issue Date : 2025-07-15
Type : Chemical
Substance Number : 712
Status : Valid
| Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-08-15
Pay. Date : 2023-09-26
DMF Number : 37799
Submission : 2023-01-16
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-16
Pay. Date : 2013-12-06
DMF Number : 22871
Submission : 2009-06-16
Status : Active
Type : II
Certificate Number : R1-CEP 2009-087 - Rev 02
Issue Date : 2022-10-04
Type : Chemical
Substance Number : 712
Status : Valid
Date of Issue : 2023-02-09
Valid Till : 2026-02-08
Written Confirmation Number : WC-0549
Address of the Firm :
NDC Package Code : 41701-007
Start Marketing Date : 2011-03-18
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (10g/10g)
Marketing Category : BULK INGREDIENT
Registrant Name : Sampung Finechem Co., Ltd.
Registration Date : 2022-05-11
Registration Number : 20210628-209-J-1042(1)
Manufacturer Name : Piramal Pharma Limited
Manufacturer Address : Plot No C-43, MIDC, TTC Industrial Area, Turbhe, Off Thane Belapur Road, Navi Mumbai Thane-400703 Maharashtra State, India

GDUFA
DMF Review : Reviewed
Rev. Date : 2016-03-30
Pay. Date : 2016-02-17
DMF Number : 30233
Submission : 2016-02-19
Status : Active
Type : II
Certificate Number : R1-CEP 2016-125 - Rev 01
Issue Date : 2023-03-31
Type : Chemical
Substance Number : 712
Status : Valid
Date of Issue : 2025-10-01
Valid Till : 2028-06-10
Written Confirmation Number : WC-0443
Address of the Firm :

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20752
Submission : 2007-07-28
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
100
PharmaCompass offers a list of Desmopressin Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Desmopressin Acetate manufacturer or Desmopressin Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Desmopressin Acetate manufacturer or Desmopressin Acetate supplier.
PharmaCompass also assists you with knowing the Desmopressin Acetate API Price utilized in the formulation of products. Desmopressin Acetate API Price is not always fixed or binding as the Desmopressin Acetate Price is obtained through a variety of data sources. The Desmopressin Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CONCENTRAID manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CONCENTRAID, including repackagers and relabelers. The FDA regulates CONCENTRAID manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CONCENTRAID API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CONCENTRAID manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CONCENTRAID supplier is an individual or a company that provides CONCENTRAID active pharmaceutical ingredient (API) or CONCENTRAID finished formulations upon request. The CONCENTRAID suppliers may include CONCENTRAID API manufacturers, exporters, distributors and traders.
click here to find a list of CONCENTRAID suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CONCENTRAID DMF (Drug Master File) is a document detailing the whole manufacturing process of CONCENTRAID active pharmaceutical ingredient (API) in detail. Different forms of CONCENTRAID DMFs exist exist since differing nations have different regulations, such as CONCENTRAID USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CONCENTRAID DMF submitted to regulatory agencies in the US is known as a USDMF. CONCENTRAID USDMF includes data on CONCENTRAID's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CONCENTRAID USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CONCENTRAID suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CONCENTRAID Drug Master File in Japan (CONCENTRAID JDMF) empowers CONCENTRAID API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CONCENTRAID JDMF during the approval evaluation for pharmaceutical products. At the time of CONCENTRAID JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CONCENTRAID suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CONCENTRAID Drug Master File in Korea (CONCENTRAID KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CONCENTRAID. The MFDS reviews the CONCENTRAID KDMF as part of the drug registration process and uses the information provided in the CONCENTRAID KDMF to evaluate the safety and efficacy of the drug.
After submitting a CONCENTRAID KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CONCENTRAID API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CONCENTRAID suppliers with KDMF on PharmaCompass.
A CONCENTRAID CEP of the European Pharmacopoeia monograph is often referred to as a CONCENTRAID Certificate of Suitability (COS). The purpose of a CONCENTRAID CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CONCENTRAID EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CONCENTRAID to their clients by showing that a CONCENTRAID CEP has been issued for it. The manufacturer submits a CONCENTRAID CEP (COS) as part of the market authorization procedure, and it takes on the role of a CONCENTRAID CEP holder for the record. Additionally, the data presented in the CONCENTRAID CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CONCENTRAID DMF.
A CONCENTRAID CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CONCENTRAID CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CONCENTRAID suppliers with CEP (COS) on PharmaCompass.
A CONCENTRAID written confirmation (CONCENTRAID WC) is an official document issued by a regulatory agency to a CONCENTRAID manufacturer, verifying that the manufacturing facility of a CONCENTRAID active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CONCENTRAID APIs or CONCENTRAID finished pharmaceutical products to another nation, regulatory agencies frequently require a CONCENTRAID WC (written confirmation) as part of the regulatory process.
click here to find a list of CONCENTRAID suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CONCENTRAID as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CONCENTRAID API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CONCENTRAID as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CONCENTRAID and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CONCENTRAID NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CONCENTRAID suppliers with NDC on PharmaCompass.
CONCENTRAID Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CONCENTRAID GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CONCENTRAID GMP manufacturer or CONCENTRAID GMP API supplier for your needs.
A CONCENTRAID CoA (Certificate of Analysis) is a formal document that attests to CONCENTRAID's compliance with CONCENTRAID specifications and serves as a tool for batch-level quality control.
CONCENTRAID CoA mostly includes findings from lab analyses of a specific batch. For each CONCENTRAID CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CONCENTRAID may be tested according to a variety of international standards, such as European Pharmacopoeia (CONCENTRAID EP), CONCENTRAID JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CONCENTRAID USP).